Bifidobacterium infantis 35624
A precise strain with significant clinical data specifically for the management of Irritable Bowel Syndrome (IBS).
Clinical Evidence
Originally classified as B. infantis (and sometimes reclassified in literature as B. longum subsp. infantis or longum 35624), this strain is unique for its extensive profiling in female patients with IBS.
Key Applications & Dosage
| Condition | Clinical Dosage | Primary Outcome |
|---|---|---|
| IBS (Global symptoms) | 1 Billion CFU/day | Reduction in bloating and pain |
The Dose-Response Anomaly
In a landmark trial (Whorwell et al., 2006), researchers tested doses of 100 million, 1 billion, and 10 billion CFU. Counterintuitively, the 1 billion CFU dose was highly effective, while the 10 billion CFU dose failed to separate from placebo. This highlights the critical principle: More CFUs does not equal better results.
FAQ
Researchers hypothesized that formulation issues at the 10B CFU level caused the bacteria to aggregate in the capsule, reducing their viability when exposed to the gut environment.